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Abstract
Aims/hypothesis Type 1 diabetes is associated with an
increased risk of vascular complications. This increased
risk could be explained by sialic acid and/or fibrinogen. It is
also not clear what explains the abolition of sex-related
differences affecting risk of CHD in the presence of type 1
diabetes. Therefore, we examined whether fibrinogen and
sialic acid are related to incident micro- and macrovascular
complications in patients with type 1 diabetes.
Methods Asubset(n=2329) of the EURODIAB Prospective
Complications Study was analysed. Sialic acid and fibrino-
gen concentrations were measured at baseline. The main
outcomes after 7 years were development of albuminuria,
retinopathy, neuropathy and CHD.
Results Univariable and multivariable models using Cox
proportional survival analyses showed that an SD unit in-
crease in sialic acid and fibrinogen levels was significantly
associated with CHD in men only. Adjusted standardised
hazard ratios (sHRs) were 1.50 (95% CI 1.05–2.15) and 1.40
(95% CI 1.06–1.86) for sialic acid and fibrinogen, respec-
tively. Initial associations between (1) sialic acid and incident
retinopathy[standardised oddsratio(sOR)men1.68,95%CI
1.10–2.57], (2) fibrinogen and retinopathy (sOR women
1.37, 95% CI 1.06–1.78) and (3) sialic acid and neuropathy
(sOR men 1.37, 95% CI 1.06–1.77) were shown, but became
non-significant in multivariable models.
Conclusions/interpretation Sialic acid and fibrinogen are
strong predictors of CHD in men with type 1 diabetes,
beyond the effect of established risk factors. The associa-
tions found with microvascular complications were not
independent of other risk factors.
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Introduction
Type 1 diabetes is associated with a four- (in men) to eight-
fold (in women) increased risk of CHD, compared with the
general population [1, 2]. This excess CHD risk in type 1
diabetes patients is not fully explained by established risk
factors. It is also not clear what explains the abolition of a
sex-related difference in CHD risk for patients with type 1
diabetes, with women being at equally high risk of devel-
oping CHD as men [3]. Concentrations of the inflammatory
markers C-reactive protein (CRP) and fibrinogen are raised
in patients with type 2 diabetes and found to be indepen-
dently related to cardiovascular morbidity and mortality in
these patients [4–7]. There is evidence that inflammation
precedes atherosclerosis and inflammation may be the
common antecedent of atherosclerosis and type 2 diabetes
[8]. Sialic acid and fibrinogen are inflammatory markers
thatarehighlycorrelatedwithCRPandcouldbeasimportant
as CRP in the prediction of CHD.
Sialic acid is the terminal sugar of the oligosaccharide
chain of acute-phase proteins. It is a molecule attached to
acute-phase proteins, such as fibrinogen, which is why both
inflammatory markers are closely related.
In the general population, elevated levels of sialic acid
havebeenshowntobeastrongpredictorofCHD[9]. In type 2
diabetic patients, associations between sialic acid and
CHD have been shown predominantly in men [10]. Since
patients with type 1 diabetes have a higher risk of devel-
oping CHD, sialic acid and/or fibrinogen could potentially
explainthisincreased risk.For fibrinogen,initial associations
with incident CHD in people with type 2 diabetes have been
shown, but multivariable analyses indicated these findings
were non-significant [4, 11, 12]. For microvascular compli-
cations, cross-sectional studies have shown elevated plasma
sialic acid concentrations in patients with type 1 and type 2
diabetes andretinopathy [13, 14] or albuminuria [13, 15–17]
compared with people without these complications. The
cross-sectional analyses of the EURODIAB study showed
elevated sialic acid concentrations in type 1 diabetic patients
with retinopathy (men), neuropathy (men) and albuminuria
(men and women), indicating the need to explore these
findings prospectively [18].
Tothebestofourknowledge,these inflammatorymarkers
have not been prospectively examined in relation to a wide
range of vascular complications in patients with type 1
diabetes. Therefore, we examined whether fibrinogen and
sialic acid are related to incident micro- and macrovascular
complications in patients with type 1 diabetes.
Methods
Study design and participants A subset of the EURODIAB
Prospective Complications Study (PCS) was used. Full
details of the methods in the EURODIAB PCS have been
published elsewhere [19–21]. The original study contained
3,250 patients with type 1 diabetes, aged between 15 and
60 years and recruited from 31 centres in 16 European
countries. Type 1 diabetes was defined as diabetes diagnosed
before the age of 36 years with a continuous need for insulin
within 1 year of diagnosis. Of those invited, 85% participat-
ed. Those with a duration of diabetes of less than 1 year and
pregnant women were excluded. Ethics committee approval
was obtained at each centre and all patients provided written
informed consent.
Measurements of risk factors All risk factors and micro-
vascular complications were measured at baseline (between
1989 and 1991) according to a standardised protocol [22].
Blood pressure was recorded twice with a random zero
sphygmomanometer(Hawskley, Lancing,UK). Hypertension
was defined as a systolic blood pressure ≥140 mmHg or
diastolic blood pressure ≥90 mmHg and/or the use of blood
pressure-lowering drugs. WHR and BMI (kg/m
2)w e r e
calculated.
Laboratory measurements A single 24 h urine collection
was performed to calculate AER at baseline after excluding
proteinuria due to urinary tract infection. Urinary albumin
was measured in a single laboratory by an immunoturbidi-
metric method (Sanofi Diagnostics Pasteur, Minneapolis,
MN, USA) [23]. A blood sample was taken to measure
plasma lipids (fasting triacylglycerol, cholesterol, HDL-
cholesterol) and HbA1c. Plasma levels of triacylglycerol
[24] and cholesterol [25] and HDL-cholesterol [26] were
assayed by standard enzymatic methods (Boehringer
Mannheim, Lewes, UK) using a centrifugal analyser (Cobas-
Bio; Roche, Welwyn Garden City, UK). For HDL, samples
with triacylglycerol concentrations >3 mmol/l were diluted
with 0.15 mol/l sodium chloride solution before chemical
precipitation. All analyses were performed centrally. LDL-
cholesterol was calculated from Friedewald’s formula if
triacylglycerol values were below 4 mmol/l [27]. Non-HDL-
cholesterol was calculated as HDL-cholesterol subtracted
from total cholesterol. HbA1c was measured centrally by an
enzyme immunoassay (Dako, Ely, UK) using a monoclonal
antibody [28].
Fibrinogen (n=1515) was assayed by a clotting assay
based on the prothrombin time, using an autoanalyser (Series
300; Instrumentation Laboratories, Lexington, MA, USA)
[29]. A pooled plasma standard, calibrated against the UK
standard (UK National Institute for Biological Standards and
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duplicate samples were included to check on reproducibility,
with satisfactory performance recorded according to the UK
National Quality Assurance guidelines. The interassay CV
was 5–8% and the intra-assay CV 4–7%. The reference
range of fibrinogen in the general population was between
5.6 and 11.2 μmol/l. Fibrinogen levels in g/l were converted
into SI units (μmol/l) by multiplying by 2.94.
Total plasma sialic acid (n=1113) was assayed using an
enzymatic method (Boehringer Mannheim), adapted for use
on a centrifugal analyser (Cobas Bio or Fara; Roche). The
between-batch coefficient of variation of the assay was 3.8%
[30]. The range for sialic acid in the general population was
between 1.6–2.2 mmol/l.
The difference in numbers at baseline (n=1515 for
fibrinogen, n=1113 for sialic acid) was due to the fact that
two separate laboratories were involved at different times
(fibrinogen first in Sheffield [31] and sialic acid [18] later at
Guy’s Hospital, London, UK).
Outcome All complications from albuminuria, retinopathy,
neuropathy and CHD were assessed during follow-up.
Albuminuria was defined as an AER above 20 μg/min. At
baseline, AER was measured once, whereas at follow-up it
was measured twice, with the mean taken as data.
Retinopathy was assessed by retinal photographs taken
according to the EURODIAB protocol [32]. Grading was
performed by the Retinopathy Grading Centre at the
Hammersmith Hospital, Imperial College London. Any reti-
nopathy contained both non-proliferative (levels 1–3) and
proliferative retinopathy (levels 4 and 5).
Total neuropathy was assessed combining peripheral
neuropathy and autonomic neuropathy. Peripheral neurop-
athy was assessed with neuropathic symptoms and signs,
including measurement of vibration perception threshold.
Autonomic neuropathy was defined as an RR ratio (the
ratio of the longest electrocardiographic RR interval
between the 28th and 32nd beats after standing to the
shortest interval between the 13th and 17th beats) of <1.04
and/or a fall in blood pressure from resting to standing of
>20 mmHg [33, 34].
CHD was defined as a previous physician diagnosis of CHD
or presence of ECG abnormalities. The former included:
myocardialinfarction,anginapectorisorcoronaryarterybypass
graft surgery. A conventional 12-lead resting ECG was
recorded on each participant. ECG abnormalities were classi-
fied by two observers according to the Minnesota Code [35].
Any discrepancies between the two observers were adjudi-
cated by a third. ECG abnormalities suggestive of probable
ischaemia consist of codes 1.1 and 1.2 (major Q/QS waves) and
code 7.1 (complete left bundle branch block). Possible
ischaemia consists of code 1.3 (minor Q waves); codes 4.1,
4.2 and 4.3 (STsegment abnormalities); and codes 5.1, 5.2 and
5.3 (Twave abnormalities). Death due to CHD causes was also
included, coded according to the International Classification of
Diseases (9th revision) classification (410–414; available from:
ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/
ICD-9/, last accessed in December 2007).
All CHD events were captured by questionnaire with
additional supporting information from hospital records,
death certificates and other healthcare documents.
Statistical analysis The statistical packages SAS (SAS 8.0;
SAS, Cary, NC, USA) and STATA 7 (Stata Statistical
Software, Release 7.0; Stata Corporation, College Station,
TX, USA) were used to perform all analyses. Spearman
rank correlations were used to test cross-sectional relation-
ships between risk factors. Non-normally distributed vari-
ables were log-transformed. For each of the outcomes,
those with baseline micro- or macrovascular complications
were excluded according to which outcome was analysed.
For the CHD analyses, 681 of the 3,250 patients at
baseline could not be assessed or were excluded from
follow-up because they did not meet the inclusion criteria at
baseline or had CHD at that time point. Of the remaining
2,569 patients, 2,329 were assessed for CHD, of whom 151
had CHD at follow-up and 2,178 did not.
For albuminuria, 1,134 patients were available without
albuminuria at baseline, 972 of whom remained normoal-
buminuric throughout the follow-up, while 162 developed
incident albuminuria. For retinopathy, 767 patients without
baseline retinopathy were available. Of these, 428 devel-
oped incident retinopathy. For neuropathy, 1,172 patients
without baseline neuropathy were available. Of these, 276
developed neuropathy and 896 did not.
To test whether the relationship between inflammatory
markers and CHD was linear, a quadratic term was fitted
for sialic acid and for fibrinogen. Likelihood ratio tests were
performed to test differences between a model including a
linear term and quadratic term, and a model with the linear
term. Evidence of non-linearity was accepted at p<0.05.
For CHD, time-to-event data were available and there-
fore univariable and multivariable Cox proportional hazards
modelling was used to estimate standardised hazard ratios
(sHR) for CHD associations with the inflammatory markers.
sHR were estimated from these models as follows: Exp
(β×SD). Interactions were tested by fitting sex × sialic acid
and sex × fibrinogen interaction terms in the Cox propor-
tional hazards models and comparing a model with sialic
acid, sex and one interaction term with the crude model
(sialic acid alone).
For microvascular outcomes, no time-to-event data were
available, but presence or absence of each complication was
assessedduring the 1997–1999follow-up visit examinations.
Therefore, univariable and multivariable logistic regression
analyses were used to analyse relationships between inflam-
Diabetologia (2008) 51:493–501 495matory markers and microvascular complications. Again,
standardised odds ratios (sORs) were presented.
Results
Sialic acid, fibrinogen and CHD The total study population
consisted of 2,329 patients, of whom 151 developed CHD.
Sialic acid and fibrinogen were measured at baseline
(1989–1991) in subsets of the total population. The mean
follow-up period was 7 years. The baseline risk factors of
those included and those lost to follow-up are given in
Table 1. In the same table, baseline characteristics between
those with and without sialic acid (or fibrinogen) measure-
ments are compared. The mean age was 32 years (SD 10,
range 15–61) and duration of diabetes 14 years (SD 9,
range 1–56). Those lost to follow-up had a markedly
greater atherogenic risk factor profile than those included in
the study. The sialic acid subset (n=1113) differed signifi-
cantly from those without sialic acid measurements (n=
1216), with an increased duration of diabetes, systolic
blood pressure, BMI in women, albumin excretion rate and
insulin dose, as well as a higher number of complications
from hypertension, retinopathy and albuminuria; there were
also more men. The patients with fibrinogen measurements
(n=1515) did not differ significantly in terms of any of the
risk factors compared with participants without these
measurements.
Sialic acid concentrations were significantly raised in
those with CHD compared with those without. Stratified by
Table 1 Baseline risk factors in the EURODIAB PCS type 1 diabetic population, including those lost to follow-up and patients with sialic acid
and fibrinogen measurements
Total population followed Lost-to-follow-up Sialic acid subset Fibrinogen subset
n=2,329 n=921 n=1,113 n=1,515
Age (years) 32.1±9.7 34.2±11.3
††† 32.2±9.7 32.0±9.5
Diabetes duration (years) 14.3±9.0 15.7±10.0
††† 14.9±9.0** 14.1±9.0
HbA1c (%)
a 8.36±1.92 8.65±1.93
††† 8.43±1.93 8.36±1.93
Systolic BP (mmHg) 120.2±16.8 124.2±19.9
††† 121.2±17.0** 120.7±16.7
Diastolic BP (mmHg) 75.0±11.2 76.7±11.9
††† 75.1±11.3 75.0±11.4
Cholesterol (mmol/l) 5.31±1.13 5.37±1.19 5.32±1.14 5.29±1.11
LDL-cholesterol (mmol/l) 3.33±0.98 3.44±1.03
† 3.34±1.00 3.34±0.97
HDL-cholesterol (mmol/l) 1.50±0.43 1.38±0.44
††† 1.50±0.44 1.51±0.42
Non HDL-cholesterol (mmol/l) 3.81±1.14 3.99±1.20
††† 3.81±1.15 3.78±1.12
Fasting triacylglycerol (mmol/l) 0.89 (0.69–1.26) 1.06 (0.78–1.58)
††† 0.91 (0.70–1.30) 0.88 (0.68–1.20)
Waist circumference (cm) (M/F)
Men 83.4±8.7 83.9±9.9 83.5±8.5 83.3±8.6
Women 75.5±8.6 78.9±12.1
††† 75.9±8.9 75.4±8.6
WHR (M/F)
Men 0.88±0.08 0.89±0.09
† 0.88±0.08 0.88±0.08
Women 0.80±0.11 0.82±0.13
††† 0.80±0.12 0.80±0.11
BMI (kg/m
2) (M/F)
Men 23.6±2.6 23.4±2.9 23.5±2.7 23.6±2.6
Women 23.3±2.9 23.8±3.5
†† 23.5±3.0* 23.3±2.9
AER (μg/min) 10.9 (6.6–23.6) 11.8 (6.2–34.4)
†† 13.1 (7.5–34.6)*** 11.0 (6.7–24.2)
Insulin dose (U day
−1 kg
−1) 0.67 (0.54–0.81) 0.63 (0.51–0.78)
††† 0.68 (0.55–0.83)** 0.67 (0.55–0.82)
Insulin injections per day 2.46±0.57 2.47±0.57 2.48±0.58 2.45±0.57
Men 52 (1,202) 51 (466) 54 (603)* 51 (771)
Hypertension (yes) 21 (493) 32 (288)
††† 23 (258)* 22 (328)
BP-lowering drugs (yes) 8 (189) 15 (138)
††† 10 (113)** 8 (122)
Lipid-lowering drugs (yes) 1.3 (31) 1.7 (15) 1.4 (16) 1.3 (20)
Current smoking 31 (719) 35 (316)
† 32 (352) 30 (460)
Ex-smoking 18 (414) 18 (162) 18 (202) 18 (275)
Retinopathy 45 (864) 50 (280)
†† 52 (468)*** 45 (560)
Albuminuria 29 (643) 35 (292)
††† 38 (418)*** 29 (433)
Neuropathy 32 (722) 48 (427)
††† 33 (363) 31 (460)
Values are means±SD, median (interquartile range) or % (n)
aHbA1c values corrected according to the DCCT method
*p<0.05, **p≤0.01, ***p≤0.001 for differences between participants with sialic acid measurements and those without (1,113 vs 1,216 patients)
†p<0.05,
††p≤0.01,
†††p≤0.001 for differences between participants lost to follow-up and those included (921 vs 2,329 patients)
496 Diabetologia (2008) 51:493–501sex, this difference was only statistically significant in men
(Table 2). Moreover, the baseline sialic acid concentration
differed by sex (p=0.04 for sialic acid × sex interaction),
with a significantly higher concentration in women than in
men (mean concentration 2.01 and 1.89 mmol/l respectively,
women vs men, p<0.0001; Table 2). The results were
similar for the relationship between fibrinogen and CHD,
which was statistically significant only in men. Again, there
was a statistically significant fibrinogen × sex interaction
(p=0.005), with a higher concentration in type 1 diabetic
women than in men (mean 9.90 μmol/l and 8.99 μmol/l
respectively, women vs men, p<0.0001).
The Spearman rank correlation coefficients between risk
factors and sialic acid or fibrinogen stratified by sex are
given in the Electronic supplementary material (ESM)
Table 1, calculated to establish potential confounders. Sta-
tisticallysignificantpositivecorrelationswerefoundbetween
sialicacidanddurationofdiabetes,HbA1c, lipid levels (apart
from HDL-cholesterol which was negative), WHR and
albumine/creatinine ratio. For fibrinogen,similar correlations
were found for most risk factors, but statistically significant
positive correlations were also found with age, BMI and both
systolicanddiastolicbloodpressure.Thecorrelationbetween
fibrinogen and sialic acid was 0.32 (p≤0.0001; 0.33 in men,
0.27 in women). Stronger correlations were found in men
than in women with inflammatory markers, especially for
lipidsandobesitymeasures.Therelationshipbetweencurrent
smoking and sialic acid was stronger in men than in women
(mean sialic acid concentration 1.95 vs 1.85 mmol/l, p=
0.0005, in men; 2.0 vs 2.0 mmol/l, p=0.8, in women
smokers vs non-smokers). For fibrinogen, by contrast, the
relationship was stronger in women than in men for smokers
vs non-smokers (mean fibrinogen levels 9.22 vs 8.88 μmol/l,
p=0.1, in men; 10.27 vs 9.76 μmol/l, p=0.03, in women).
Linearity was checked for the relationships between
inflammatory markers and CHD. There was no evidence of
a non-linear relationship (p=0.09 for sialic acid and p=0.4
for fibrinogen in likehood ratio test). There was also no
evidence of non-linearity when findings were stratified by
sex. The linearity of the relationship was shown by the
increasing hazard ratios (HRs) with quartiles of sialic acid
concentrations. Thus HRs changed from 1.0 to 4.7 (p=
0.047) and from 5.9 (p=0.02) to 8.3 (p=0.006) respectively
for sialic acid levels <1.7, 1.7–1.9, 1.9–2.2 and ≥2.2 mmol/l.
The main analyses for CHD are shown in Table 3.I n
univariable models, an increase in one SD unit of baseline
sialic acid concentration was related to a 1.6-fold increased risk
of CHD, but only for men. Similarly, for fibrinogen, a sHR of
1.7 was found, but only for men. In women, no statistically
significant association between sialic acid or fibrinogen and
CHD was observed. In multivariable models, there was still a
clear 1.5-fold increased risk of CHD with increasing concen-
trations of sialic acid when adjusted for age, diabetes duration,
HbA1c, triacylglycerol, WHR, current smoking, systolic blood
pressure and AER, but only in men. Similarly, for fibrinogen,
there was a 1.4-fold increased risk of CHD in multivariable
models, also only in men. Since albuminuria is an important
risk marker for CHD, adjustment for this marker attenuated the
relationship between fibrinogen and CHD. Smoking did not
affect the relationship between fibrinogen and CHD. Adjust-
ment for centre and the use of blood pressure-lowering or lipid-
lowering drugs did not alter the results.
Sialic acid, fibrinogen and microvascular complications Sta-
tistically significant univariable associations were shown
between: (1) sialic acid and incident retinopathy in men
(sOR 1.68, 95% CI 1.10–2.57); (2) fibrinogen and retinop-
athy in women (sOR 1.37, 95% CI 1.06–1.78); and (3) sialic
acid and neuropathy in men (sOR 1.37, 95% CI 1.06–1.77;
Table 4). Theseassociations,however,becamenon-significant
in multivariable models (adjusting for age, diabetes duration
and HbA1c). There was no relationship between sialic acid or
fibrinogen with albuminuria in univariable analyses.
Discussion
Sialic acid and fibrinogen are significant predictors of CHD
in men with type 1 diabetes. These relationships are inde-
pendent ofestablished risk factors, supportingthe hypothesis
Table 2 Unadjusted baseline sialic acid and fibrinogen concentrations by CHD status per group at follow-up
Total group Men Women
CHD No CHD CHD No CHD CHD No CHD
Sialic acid concentrations available (n) 68 1,045 31 572 34 473
Sialic acid (mmol/l) 2.06±0.36** 1.94±0.38 2.09±0.35*** 1.88±0.35 2.04±0.38 2.01±0.40
Fibrinogen concentrations available (n) 92 1,423 46 725 46 698
Fibrinogen (μmol/l) 10.06±3.26* 9.40±2.75 10.37±3.64*** 8.90±2.63 9.74±2.84 9.91±2.79
Values are means±SD
*p<0.05, **p≤0.01, ***p≤0.001 vs corresponding control
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The associations found with microvascular complications
were explained by other risk factors.
The reasons for a difference in the relationship between
sialic acid or fibrinogen and CHD in men and women are
unknown, but this difference could explain the abolition of
a sex-related difference in CHD risk in people with type 1
diabetes. The levels of both inflammatory markers were
higher in women than in men with type 1 diabetes, but not
outside the reference range in the general population. The
levels of sialic acid and fibrinogen were significantly higher
in patients with CHD than in those without and were at the
upper end of the normal range. It is not entirely clear why
sialic acid and fibrinogen are related to CHD only in men.
This relation has been found previously in a cross-sectional
analysis of the Guy’s and Lewisham Hospitals Surveys,
where the main conclusion was that there were univariate
associations between elevated sialic acid concentrations and
CHD in men (but not women) with type 2 diabetes [10].
The finding that the concentrations of sialic acid and fibrin-
ogen were statistically significantly higher in women than
in men with type 1 diabetes indicates different mechanisms
in the two sexes.
It could be said that sialic acid and fibrinogen do not
constitute a component cause of CHD development in
women, because there may be other essential causes, which
are more important. The correlations between the inflamma-
tory markers and lipids, obesity measures and smoking were
strongerinmenthaninwomen,butadjustingforthese would
diminish the relationship between these inflammatory
markers and CHD in men. This strong association persisted,
however, after adjustment for all these factors, so this could
notexplainthe sex-relateddifference.Another possibleexpla-
nation for the predictive value of inflammatory markers in
men, but not in women, could be the possibility that the
relationship between sialic acid or fibrinogen and CHD was
not linear in women, with a flattening of the relationship
towards the end.Inthiscase,the CHD riskwouldnot increase
any longer. However, this was not true in our data, since for
menandwomenthere was noevidenceofnon-linearity.Sialic
Table 4 Risk of developing albuminuria, retinopathy and neuropathy during the follow-up period by 1 SD unit increase in inflammatory markers
Sialic acid Fibrinogen
Men Women Men Women
Albuminuria, crude model 0.94 (0.67–1.31) 1.28 (0.83–1.96) 0.92 (0.67–1.26) 1.30 (0.98–1.73)
Retinopathy
Crude model 1.68 (1.10–2.57)** 1.17 (0.87–1.56) 1.05 (0.81–1.37) 1.37 (1.06–1.78)*
Adjusted for age and diabetes duration 1.61 (1.04–2.48)* 1.11 (0.82–1.50) 1.06 (0.80–1.41) 1.39 (1.06–1.81)*
Adjusted as above plus for HbA1c 1.43 (0.91–2.23) 1.28 (0.96–1.71)
Neuropathy
Crude model 1.37 (1.06–1.77)* 0.93 (0.70–1.23) 1.25 (0.97–1.62) 0.88 (0.69–1.11)
Adjusted for age and diabetes duration 1.36 (1.04–1.77)* 0.96 (0.72–1.28) 1.15 (0.88–1.51) 0.87 (0.68–1.10)
Adjusted as above plus for HbA1c 1.26 (0.96–1.66)
Values are sOR (95% CI)
*p<0.05, **p≤0.01
Table 3 Risk of CHD by 1 SD increase in inflammatory markers
Sialic acid Fibrinogen
CHD in men CHD in women CHD in men CHD in women
n 603 510 771 744
Events (n)3 1 3 7 4 6 4 6
Crude model 1.59 (1.21–2.09)*** 1.04 (0.77–1.41) 1.69 (1.32–2.16)*** 0.99 (0.74–1.31)
Adjustment 1
a 1.64 (1.22–2.21)*** 1.07 (0.78–1.49) 1.50 (1.16–1.95)** 1.00 (0.75–1.33)
Adjustment 2
b 1.50 (1.05–2.15)* 0.95 (0.67–1.35) 1.23 (0.88–1.70) 0.81 (0.61–1.09)
Adjustment 3
c 1.40 (1.06–1.86)** 0.90 (0.66–1.21)
Unless otherwise indicated, values are sHR (95% CI)
aAdjusted for age and diabetes duration
bAdjusted for HbA1c, triacylglycerol, WHR, smoking, systolic blood pressure and AER
cAdjusted for HbA1c, triacylglycerol, WHR, smoking, systolic blood pressure, but not AER
*p<0.05, **p≤0.01, ***p≤0.001
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glycoproteins, particularly some of the acute-phase proteins
and is (biologically) bound to fibrinogen. We found that the
results for fibrinogen and sialic acid were similar, which adds
weight to our conclusion that acute-phase or inflammatory
markers are strong predictors of CHD risk in type 1 diabetes.
In the general population, a large Swedish study with a
20 year follow-up reported a 1.9-fold increased CHD
mortality risk in 50,000 non-diabetic men and women with
increased concentrations of sialic acid [9]. More recently,
the 17 year prospective Busselton (WA, Australia) Health
Survey of 1,612 non-diabetic men and women reported that
a 0.8 mmol/l increase in sialic acid was significantly asso-
ciated with a HR of 1.21 (95% CI 1.02–1.45) for CHD
events, with men having an HR of 1.06 (95% CI 0.82–1.37)
and women an HR of 1.40 (95% CI 1.11–1.76) [36]. The
evidence of a relationship between sialic acid and CHD in
patients with type 1 or type 2 diabetes is scarce. A 13 year
follow-up study in type 2 diabetes found that sialic acid or
‘activator of the innate immune system’ was a strong
independent predictor of CVD mortality in patients with
type 2 diabetes [8]. We have now found that this ‘activation
of the innate immune system’ is also present in patients
with type 1 diabetes and highly predictive of CHD.
The relationship between sialic acid and incident micro-
vascular complications did not seem to be very strong in
our data, especially when analysed in multivariable models.
Previously it has been shown that elevated sialic acid con-
centrations were cross-sectionally associated with diabetic
retinopathy in patients with type 1 [13] and type 2 diabetes
[14]. These studies used small study populations and no
adjustment for confounders was carried out. For albumin-
uria, several studies have found a positive relationship with
sialic acid in patients with type 1 diabetes [13, 16, 17],
including one prospective study assessing sialic acid levels
3 years before diagnosis of microalbuminuria [37]. It is
conceivable that sialic acid concentration plays a role only
in early diabetic nephropathy [17, 37], possibly explaining
why we failed to find any relationship with albuminuria
after 7 years. For neuropathy, one study in type 1 diabetes
showed no relationship with sialic acid [13].
There is extensive evidence from prospective studies and
meta-analyses in the general population that fibrinogen
predicts CHD in individuals with and without prior vascular
disease, with relative risks of around 2 being reported
[38–41]. In patients with type 1 or type 2 diabetes, the
evidence is less clear. Elevated concentrations of fibrinogen
have been demonstrated in patients with type 2 diabetes
[11, 12, 42], but the relationship between fibrinogen and
CVD seemed to be diminished after further risk factor
adjustments [4, 11]. Both of these studies adjusted for a
wide range of risk factors, but not for albuminuria. We have
demonstrated that fibrinogen also predicts CHD in patients
with type 1 diabetes, although this association was no longer
statistically significant after further adjustment for albumin-
uria. Because fibrinogen levels can be reduced considerably
bylifestyle interventions (suchasphysicalexercise,smoking
cessation and moderate alcohol consumption) that also affect
levels of established risk factors, the possibility of measuring
fibrinogen in order to prevent or predict future CHD is
clearly of interest. In our data, although participants who
smoked had higher levels of fibrinogen than none smokers,
adjustment for smoking did not seem to affect the relation-
ship between fibrinogen and CHD in any way.
The EURODIAB PCS offers the possibility to study
complications of type 1 diabetes, as it provides a large,
multicentre, European cohort of patients attending a clinic
at least once a year. In addition, all centres used similar
standardised methods. In the current study enough coronary
events haveaccrued overa long follow-up period to carry out
powerful analyses. However, because some centres did not
participateinthesemeasurementsandsamplesweretherefore
not available, a large number of measurements of sialic acid
were not available. Participants lost-to-follow-up had a
slightly more atherogenic profile, which could have led to
overestimation of the true association between sialic acid or
fibrinogen and CHD incidence.
The study question was decided upon a priori and the
relevant statistical tests were applied accordingly, not testing
for every conceivable association. Adjustment for centre did
not affect results. Residual confounding could have played a
role, since all baseline variables were measured only once,
thereby possibly underestimating the role of confounding.
Nevertheless, strong associations were found for sialic acid
and fibrinogen, indicating that residual confounding could
not wholly account for our findings.
In conclusion, in this large prospective Europe-wide
cohort study of patients with type 1 diabetes, sialic acid and
fibrinogen were found to be significant and independent
predictors of CHD in men, supporting the hypothesis that
inflammation plays a role in the development of CHD. No
independent associations were found with microvascular
complications. The finding that both of these inflammatory
markers are related to CHD only in men needs to be explored
further.
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